Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FCGR2B
REST API REST API
Homo sapiens
FCGR2B is differentially expressed in 235 experiments: 140 organism parts: placenta, bone marrow, ... (138 more);, 199 disease states: normal, glioblastoma, ... (197 more);, 90 cell types 260 cell lines 23 compound treatments and 74 other conditions.
Synonyms CD32B, FCG2, CD32, FCGR2
Orthologs Fcgr3 (Mus musculus)   Fcgr2b (Mus musculus)   A8DC37_BOVIN (Bos taurus)   ENSGALG00000010507 (Gallus gallus)   FCGR2_BOVIN (Bos taurus)   Fcgr2a (Rattus norvegicus)   ENSXETG00000000093 (Xenopus laevis)   ENSXETG00000033086 (Xenopus laevis)   fcrl2 (Xenopus laevis)   fcrl3 (Xenopus laevis)   ENSXETG00000019988 (Xenopus laevis)   XB-GENE-5897202 (Xenopus laevis)   ENSXETG00000030865 (Xenopus laevis)   ENSXETG00000027522 (Xenopus laevis)   ENSXETG00000008724 (Xenopus laevis)   XB-GENE-5946284 (Xenopus laevis)   ENSXETG00000008730 (Xenopus laevis)   XB-GENE-5844396 (Xenopus laevis)   ENSXETG00000031558 (Xenopus laevis)   LOC100489476 (Xenopus laevis)   XB-GENE-5960290 (Xenopus laevis)   ENSXETG00000027430 (Xenopus laevis)   XB-GENE-5991223 (Xenopus laevis)   LOC100492146 (Xenopus laevis)   ENSXETG00000012605 (Xenopus laevis)   LOC100485196 (Xenopus laevis)   LOC100496351 (Xenopus laevis)   ENSXETG00000027519 (Xenopus laevis)   ENSXETG00000014567 (Xenopus laevis)   XB-GENE-5888675 (Xenopus laevis)   ENSXETG00000032513 (Xenopus laevis)   LOC100497613 (Xenopus laevis)   ENSXETG00000015990 (Xenopus laevis)   ENSXETG00000029984 (Xenopus laevis)   ENSXETG00000030992 (Xenopus laevis)   ENSXETG00000031422 (Xenopus laevis)   LOC100491172 (Xenopus laevis)   ENSXETG00000013088 (Xenopus laevis)   LOC100495438 (Xenopus laevis)   LOC100493362 (Xenopus laevis)   ENSXETG00000033554 (Xenopus laevis)   ENSXETG00000026888 (Xenopus laevis)   LOC100488808 (Xenopus laevis)   ENSCAFG00000013035 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, receptor activity, immune response, integral to membrane, signal transduction, regulation of immune response, IgG binding, interspecies interaction between organisms
InterPro Term Ig_sub, Ig-like, Ig_sub2
UniProt Accession Q8IZV7, P31994, Q8IU79, Q8NIA0, Q8NI89
Gene-Disease Assocation MALARIA, SUSCEPTIBILITY TO, SYSTEMIC LUPUS ERYTHEMATOSUS; SLE
Search EB-eye ENSG00000072694
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-1880, E-GEOD-19639, E-GEOD-2450, ... (23 experiments)

Factor Value U/D Experiments
SW480
2
E-MEXP-1014, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
HT1197
1
E-MTAB-37
DMS153
1
E-MTAB-37
GM10842
1
E-TABM-321
NA19128
1
E-GEOD-19480
254 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (40 experiments)

Factor Value U/D Experiments
B cell
3
2
E-GEOD-3982, E-GEOD-13987
CD34+
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, E-GEOD-16363, ... (58 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-96
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-2466
colon carcinoma
2
E-MTAB-37, E-MTAB-62
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
193 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-TABM-868, E-GEOD-5099, E-MEXP-1958, ... (19 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-412, E-GEOD-2803, E-TABM-868, E-MEXP-1958, E-MEXP-1230, ... (6 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
no estradiol
1
E-GEOD-20081
placebo
1
E-MEXP-1327
glucose
1
E-MEXP-941
17 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
90 years
1
1
E-GEOD-4922


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, ... (6 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22544, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-17385

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-GEOD-3624, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20540, E-MEXP-1446, E-MEXP-1103, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (35 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-2634, E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-22309, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19743, E-GEOD-2508, E-GEOD-19069, E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-4922

Processing time: 0.322 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM